BAYCOX BOVIS 50 MG/ML ORAL SUSPENSION
Country: Írland
Tungumál: enska
Heimild: HPRA (Health Products Regulatory Authority)
Vara einkenni
(SPC)
28-04-2024
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
TOLTRAZURIL
Fáanlegur frá:
Bayer Limited
ATC númer:
QP51AJ01
INN (Alþjóðlegt nafn):
TOLTRAZURIL
Skammtar:
50 Mg/Ml
Lyfjaform:
Oral Suspension
Gerð lyfseðils:
POM
Meðferðarhópur:
Bovine
Lækningarsvæði:
Toltrazuril
Ábendingar:
Coccidiostats
Leyfisstaða:
Authorised
Leyfisdagur:
2006-01-25
Vara einkenni
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Baycox Bovis 50mg/ml oral suspension.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Oral suspension.
White or yellowish suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (calves on dairy farms).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the prevention of clinical signs of coccidiosis and reduction of coccidia shedding in housed calves replacing cows
producing milk for human consumption (dairy cows) on farms with a confirmed history of coccidiosis caused by
_Eimeria bovis _or _Eimeria zuernii_.
4.3 CONTRAINDICATIONS
For environmental reasons:
Do not use in calves weighing more than 80 kg bodyweight.
Do not use in fattening units such as veal or beef calves.
For more details see sections 4.5, other precautions and section 5, environmental properties.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
As with any antiparasiticide frequent and repeated use of antiprotozoals from the same class may lead to the
development of resistance.
It is recommended to treat all calves in a pen
Hygienic measures may reduce the risk of bovine coccidiosis. It is therefore, recommended to improve concomitantly
the hygienic conditions in the concerned facility, particularly dryness and cleanliness.
To obtain maximum benefit, animals should be treated before the expected onset of clinical signs, i.e. in the prepatent
period.
To alter the course of an established clinical coccidial infection, in individual animals already showing signs of
diarrhoea, additional supportive therapy may be required.
1 ml contains:
ACTIVE SUBSTANCE:
Toltrazuril
50.0 mg
EXCIPIENT(S):
Sodium benzoate (E211)
2.1 mg
Sodium propionate (E281)
2.1 mg
For a full list of excipients, see section 6.1.
IRISH MEDICINES BOARD
____
Lestu allt skjalið
